Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.

[1]  Haroon,et al.  A bibliometric analysis of the top 100 most cited papers and research trends in breast cancer related BRCA1 and BRCA2 genes , 2022, Medicine.

[2]  R. Plummer,et al.  An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib , 2016, Targeted Oncology.

[3]  Karen So,et al.  Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors , 2015, Advances in Therapy.

[4]  N. Waters.  Evaluation of drug-drug interactions for oncology therapies: in vitro-in vivo extrapolation model-based risk assessment. , 2015, British journal of clinical pharmacology.

[5]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .

[6]  R. Schmutzler,et al.  Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study. , 2013 .

[7]  Y. Pommier,et al.  Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.

[8]  H. Mackay,et al.  Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. , 2011, The Lancet. Oncology.

[9]  N. C. van de Merbel,et al.  A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. , 2011, Journal of pharmaceutical and biomedical analysis.

[10]  P. Neuvonen,et al.  Itraconazole, a P‐Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin‐Inhibiting Effect of Aliskiren , 2011, Journal of clinical pharmacology.

[11]  L. Bertilsson,et al.  4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. , 2011, British journal of clinical pharmacology.

[12]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[13]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[14]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[15]  L Zhang,et al.  The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies , 2008, Clinical pharmacology and therapeutics.

[16]  A. Lau,et al.  Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin , 2008, Clinical Cancer Research.

[17]  R. Bertz,et al.  Effect of Rifampin on Steady-State Pharmacokinetics of Atazanavir with Ritonavir in Healthy Volunteers , 2006, Antimicrobial Agents and Chemotherapy.

[18]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[19]  R. Bertz,et al.  Pharmacokinetics of Adjusted-Dose Lopinavir-Ritonavir Combined with Rifampin in Healthy Volunteers , 2004, Antimicrobial Agents and Chemotherapy.

[20]  K. Ruxrungtham,et al.  Lack of Enzyme‐Inducing Effect of Rifampicin on the Pharmacokinetics of Enfuvirtide , 2003, Journal of clinical pharmacology.

[21]  P. Neuvonen,et al.  The area under the plasma concentration–time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin , 1998, European Journal of Clinical Pharmacology.

[22]  J. Thigpen.  Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer , 2012 .

[23]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[24]  L. Bertilsson,et al.  4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. , 2009, British journal of clinical pharmacology.

[25]  R. Namdar,et al.  Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids. , 1999, Chest.

[26]  S. Kaneko,et al.  Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam , 2022 .